DongKoo Bio & Pharma Co. Ltd. - Asset Resilience Ratio

Latest as of June 2026: 10.24%

DongKoo Bio & Pharma Co. Ltd. (006620) has an Asset Resilience Ratio of 10.24% as of June 2026. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See 006620 net working capital ratio to evaluate short-term liquidity relative to the company's equity base.

Liquid Assets

₩32.64 Billion
≈ $22.12 Million USD Cash + Short-term Investments

Total Assets

₩318.60 Billion
≈ $215.91 Million USD All company assets

Resilience Assessment

Moderate
Financial Resilience Level

Asset Resilience Ratio Trend (2015–2025)

This chart shows how DongKoo Bio & Pharma Co. Ltd.'s Asset Resilience Ratio has changed over time. For the complete balance sheet picture, see DongKoo Bio & Pharma Co. Ltd. (006620) total assets.

Liquid Assets Composition Over Time

This chart breaks down DongKoo Bio & Pharma Co. Ltd.'s liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. Explore 006620 long-term investment intensity to see how much of total assets are deployed in long-term investments.

Current Liquid Assets Breakdown

Component Amount % of Total Assets
Cash & Equivalents ₩0.00 0%
Short-term Investments ₩32.64 Billion 10.24%
Total Liquid Assets ₩32.64 Billion 10.24%

Asset Resilience Insights

  • Moderate Liquidity: DongKoo Bio & Pharma Co. Ltd. has 10.24% of assets in liquid form.
  • While adequate for normal operations, this level may limit flexibility during economic stress.
  • The company has significant short-term investments, indicating active treasury management.

DongKoo Bio & Pharma Co. Ltd. Industry Peers by Asset Resilience Ratio

Compare DongKoo Bio & Pharma Co. Ltd.'s asset resilience ratio with other companies in the same industry.

Company Industry Asset Resilience Ratio
Theragen Etex Co.Ltd
KQ:066700
Pharmaceuticals 0.68%
Sam Chun Dang Pharm. Co. Ltd
KQ:000250
Pharmaceuticals 6.87%
ST Pharm Co.Ltd
KQ:237690
Pharmaceuticals 7.72%
NatureCell Co.Ltd
KQ:007390
Pharmaceuticals 0.00%
Oscotec Inc
KQ:039200
Pharmaceuticals 65.38%
Mezzion Pharma Co.Ltd
KQ:140410
Pharmaceuticals 13.09%
Komipharm International Co. Ltd
KQ:041960
Pharmaceuticals 0.00%
Caregen Co.Ltd
KQ:214370
Pharmaceuticals 4.58%

Annual Asset Resilience Ratio for DongKoo Bio & Pharma Co. Ltd. (2015–2025)

The table below shows the annual Asset Resilience Ratio data for DongKoo Bio & Pharma Co. Ltd..

Year Asset Resilience Ratio (%) Liquid Assets Total Assets Change
2025-12-31 4.04% ₩13.60 Billion
≈ $9.22 Million
₩336.35 Billion
≈ $227.94 Million
-10.81pp
2024-12-31 14.85% ₩36.24 Billion
≈ $24.56 Million
₩244.06 Billion
≈ $165.40 Million
+2.87pp
2023-12-31 11.98% ₩22.90 Billion
≈ $15.52 Million
₩191.10 Billion
≈ $129.51 Million
-8.23pp
2022-12-31 20.22% ₩34.79 Billion
≈ $23.57 Million
₩172.06 Billion
≈ $116.60 Million
-0.43pp
2021-12-31 20.65% ₩31.96 Billion
≈ $21.66 Million
₩154.79 Billion
≈ $104.90 Million
+0.20pp
2020-12-31 20.44% ₩29.51 Billion
≈ $20.00 Million
₩144.35 Billion
≈ $97.83 Million
-4.17pp
2019-12-31 24.61% ₩32.67 Billion
≈ $22.14 Million
₩132.73 Billion
≈ $89.95 Million
+3.81pp
2018-12-31 20.80% ₩21.69 Billion
≈ $14.70 Million
₩104.28 Billion
≈ $70.67 Million
+6.27pp
2017-12-31 14.54% ₩10.99 Billion
≈ $7.45 Million
₩75.59 Billion
≈ $51.23 Million
+7.00pp
2016-12-31 7.54% ₩4.92 Billion
≈ $3.34 Million
₩65.31 Billion
≈ $44.26 Million
+7.14pp
2015-12-31 0.39% ₩240.00 Million
≈ $162.65K
₩60.77 Billion
≈ $41.18 Million
--
pp = percentage points

About DongKoo Bio & Pharma Co. Ltd.

KQ:006620 Korea Pharmaceuticals
Market Cap
$22.84 Million
₩33.71 Billion KRW
Market Cap Rank
#24777 Global
#1784 in Korea
Share Price
₩3510.00
Change (1 day)
+0.57%
52-Week Range
₩3450.00 - ₩6090.00
All Time High
₩13745.55
About

DongKoo Bio&Pharma. Co., Ltd. researches, develops, manufactures, and sells medicines in South Korea. The company offers prescribed medicines, such as liver disease, skeletal muscle relaxant, endocrine system, brain nervous system, urogenital, antiobestic, digestive system, circulatory organ, allergenic, mental disease, oral dermatology, external preparation of dermatology, antiseptic, antiviral,… Read more